<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588313</url>
  </required_header>
  <id_info>
    <org_study_id>BTS910/15</org_study_id>
    <nct_id>NCT02588313</nct_id>
  </id_info>
  <brief_title>Investigation of Long-term Effects of CarelessTM on Microcirculation</brief_title>
  <official_title>Investigation of Long-term Effects of CarelessTM on Microcirculation in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vital Solutions Swiss AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vital Solutions Swiss AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to investigate long-term effects of CarelessTM, a Mangifera indica fruit&#xD;
      powder on microcirculation and endothelial function after supplementation of 4 weeks. Effects&#xD;
      will be investigated with 100mg and 300mg CarelessTM and compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study is to investigate long-term effects of CarelessTM, a Mangifera indica fruit&#xD;
      powder on microcirculation and endothelial function after supplementation of 4 weeks. Effects&#xD;
      will be investigated with 100mg and 300mg CarelessTM and compared to placebo.&#xD;
&#xD;
      To describe targeted parameter, cutaneous microcirculation will be measured at 1 mm depth as&#xD;
      well as flow mediated endothelial function at the beginning and end of supplementation, each.&#xD;
      Furthermore, the parameters will be determined postprandially 1 hour after glucose loading.&#xD;
      Additionally the influence on the glucose metabolism, as well as on body weight and body fat&#xD;
      will be documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of circulation</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Measurement of dermal microcirculation using &quot;O2C, Lea Technik&quot;:&#xD;
Relative peripheral blood flow (LDF)&#xD;
Venous oxygen saturation (SO2 ven)&#xD;
Relative amount of haemoglobin (rHb). Delta change of dermal microcirculation from baseline to end of supplementation is investigated. Addi-tionally, the delta change of dermal microcirculation from baseline to end of supplementation post-prandial is determined, which means the evaluation of postprandial effects on reactive hyperaemia index after glucose load.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of glucose related biomarker</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Measurement of Biomarker HOMA-Index, HbA1c at baseline and end of supplementation under fasting conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire on fatigue and vigor</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Questionnaire on fatigue and vigor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of adverse effects</measure>
    <time_frame>During study execution over 4 weeks</time_frame>
    <description>Reporting of adverse effects to evaluate tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of endothelial function using &quot;EndoPATTM, Itamar&quot;</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Measurement of endothelial function using &quot;EndoPATTM, Itamar&quot;&#xD;
Reactive hyperaemia index (RHI and lnRHI)&#xD;
Arterial stiffness (AI75) Delta change of endothelial function and arterial stiffness from baseline to end of supplementation is investigated. Additionally, the delta change of endothelial function from baseline to end of supplemen-tation postprandial is determined, which means the evaluation of postprandial effects on relative hy-peraemia index after glucose load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of ox LDL</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Measurement of ox LDL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation</time_frame>
    <description>Body weight and body fat (Body impedance analysis) determination</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood glucose</measure>
    <time_frame>Baseline at day 1 and after 4 weeks supplementation, before 1h and 2h after glucose loading</time_frame>
    <description>Capillary blood glucose</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Disorder of Circulatory System</condition>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Mango fruit powder 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mango fruit powder 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mango fruit powder 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mango fruit powder 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo formulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mango fruit powder</intervention_name>
    <description>Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design</description>
    <arm_group_label>Mango fruit powder 100mg</arm_group_label>
    <arm_group_label>Mango fruit powder 300mg</arm_group_label>
    <arm_group_label>Placebo formulation</arm_group_label>
    <other_name>CarelessTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Men and postmenopausal women&#xD;
&#xD;
          -  HOMA Index ≥2 and &lt;5&#xD;
&#xD;
          -  BMI: 19 - 30 kg/m2&#xD;
&#xD;
          -  Age ≥ 40 and ≤ 70 years&#xD;
&#xD;
          -  Nonsmoker&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
          -  Able and willing to follow the study protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant history, presence of any medical disorder or chronic intake of&#xD;
             medication/dietary sup-plements (e.g. polyphenols, L-Arginine, Niacin, medication of&#xD;
             haemodilution, blood flow stimu-lating products like Aspirin (Acetylsalicylsäure),&#xD;
             Clopidogrel (Adenosin-Diphosphat(ADP)-Inhibitors), Glykoprotein-IIb/IIIa-Inhibitors,&#xD;
             Heparin, Marcumar (Vitamin K antagonists); Dabiga-tran (Faktor IIa synthese&#xD;
             Inhibitors) Rivaroxaban (Faktor Xa Antagonist), Statins) potentially in-terfering with&#xD;
             this study at screening.&#xD;
&#xD;
          -  For this study clinically relevant abnormal laboratory, vital signs or physical&#xD;
             findings at screening&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Atopic dermatitis or affected skin at the forearm&#xD;
&#xD;
          -  Injury on the finger, influencing the EndoPATTM measurement&#xD;
&#xD;
          -  Regular consumption of caffeine &gt; 275 mg (equivalent to 3-4 cups of coffee or 9 cups&#xD;
             of black tea)&#xD;
&#xD;
          -  Change of dietary habits within the 2 weeks prior to screening (for instance start of&#xD;
             a diet high in vegetables and fruits (≥ 5 portions per day))&#xD;
&#xD;
          -  Diet high in vegetables and fruits ≥ 5 portions per day&#xD;
&#xD;
          -  Participants anticipating a change in their lifestyle or physical activity levels&#xD;
             during the study.&#xD;
&#xD;
          -  Subjects not willing to avoid polyphenol rich foods and abstain from beverages&#xD;
             containing caf-feine the day prior to visit 1 and 2.&#xD;
&#xD;
          -  Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24&#xD;
             hours prior to and during visit 1 and 2.&#xD;
&#xD;
          -  Sunbathing or the use of sun-beds 2 weeks prior to study days&#xD;
&#xD;
          -  Subjects with history of drug, alcohol or other substances abuse, or other factors&#xD;
             limiting their ability to co-operate during the study.&#xD;
&#xD;
          -  Known hypersensitivity to the study preparation or to single ingredients&#xD;
&#xD;
          -  Pregnant subject or subject planning to become pregnant during the study;&#xD;
             breast-feeding sub-ject.&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  Known acute or chronic hepatitis B and C infection&#xD;
&#xD;
          -  Blood donation within 4 weeks prior to visit 1 or during the study.&#xD;
&#xD;
          -  Subject involved in any clinical or food study within the preceding month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Reule, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>BioTeSys GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

